Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion

International Journal of Radiation Oncology Biology Physics

Volumn 91, Issue 5, 2015, Pages 942-951

  Nyflot, Matthew J ^a   Kruser, Tim J ^b   Traynor, Anne M ^c   Khuntia, Deepak ^d   Yang, David T ^c   Hartig, Gregory K ^c   McCulloch, Timothy M ^c   Wiederholt, Peggy A ^c   Gentry, Lindell R ^c   Hoang, Tien ^c   Jeraj, Robert ^c   Harari, Paul M ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b 300 S Randell Rd   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d VARIAN MEDICAL SYSTEMS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMORADIOTHERAPY; POSITRON EMISSION TOMOGRAPHY; TOXICITY; TUMORS;

CHEMORADIATION THERAPIES; CONCURRENT CHEMORADIATION; CONTRAST ENHANCEMENT; DOSE LIMITING TOXICITY; DYNAMIC CONTRAST ENHANCED; METHODS AND MATERIALS; SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECKS; TUMOR PROLIFERATION;

COMPUTERIZED TOMOGRAPHY;

BEVACIZUMAB; CISPLATIN; HEMOGLOBIN; ANTINEOPLASTIC AGENT; COPPER (II) DIACETYL-DI(N(4)-METHYLTHIOSEMICARBAZONE); MONOCLONAL ANTIBODY; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT; THIOSEMICARBAZONE DERIVATIVE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BLOOD FLOW; BLOOD VOLUME; CANCER GROWTH; CANCER RECURRENCE; CANDIDIASIS; CELLULITIS; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG SAFETY; DYSGEUSIA; DYSPHAGIA; ESOPHAGUS CANDIDIASIS; FATIGUE; FEMALE; FOLLOW UP; GASTRITIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERTENSION; HYPONATREMIA; LEG EDEMA; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NECK DISSECTION; NEUTROPENIA; ORAL BLEEDING; ORAL CAVITY HEMORRHAGE; PAIN; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR HYPOXIA; TUMOR PAIN; VOMITING; WEIGHT REDUCTION; ADVERSE EFFECTS; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL PROLIFERATION; CLINICAL TRIAL; DRUG ADMINISTRATION; HEAD AND NECK NEOPLASMS; INDUCTION CHEMOTHERAPY; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; SCINTISCANNING; VASCULARIZATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL PROLIFERATION; CHEMORADIOTHERAPY; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THIOSEMICARBAZONES;

EID: 84925349489     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.11.029     Document Type: Article

References (40)

1. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11 2010 21 28
2. J.B. Vermorken, R. Mesia, and F. Rivera Platinum-based chemotherapy plus cetuximab in head and neck cancer N Engl J Med 359 2008 1116 1127
3. P.A. Kyzas, I.W. Cunha, and J.P. Ioannidis Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: A meta-analysis Clin Cancer Res 11 2005 1434 1440
4. M.F. Adam, E.C. Gabalski, and D.A. Bloch Tissue oxygen distribution in head and neck cancer patients Head Neck 21 1999 146 153
5. M. Nordsmark, S.M. Bentzen, and V. Rudat Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy: An international multi-center study Radiother Oncol 77 2005 18 24
6. R.K. Jain Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy Science 307 2005 58 62
7. A. Bozec, A. Sudaka, and J.L. Fischel Combined effects of bevacizumab with erlotinib and irradiation: A preclinical study on a head and neck cancer orthotopic model Br J Cancer 99 2008 93 99
8. T. Hoang, S. Huang, and E. Armstrong Enhancement of radiation response with bevacizumab J Exp Clin Cancer Res 31 2012 37
9. A.F. Shields, J.R. Grierson, and B.M. Dohmen Imaging proliferation in vivo with [F-18]FLT and positron emission tomography Nat Med 4 1998 1334 1336
10. Y. Menda, L.L. Boles Ponto, and K.J. Dornfeld Kinetic analysis of 3′-deoxy-3′-18F-fluorothymidine (18F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy J Nucl Med 50 2009 1028 1035
11. Y. Fujibayashi, H. Taniuchi, and Y. Yonekura Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential J Nucl Med 38 1997 1155 1160
12. 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: A pilot study Ann Nucl Med 25 2011 339 345
13. R. Hermans, M. Meijerink, and W. Van den Bogaert Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy Int J Radiat Oncol Biol Phys 57 2003 1351 1356
14. C.G. Willett, Y. Boucher, and E. di Tomaso Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2004 145 147
15. R.L. Wahl, H. Jacene, and Y. Kasamon From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors J Nucl Med 50 Suppl 1 2009 122S 150S
16. M. Muzi, D.A. Mankoff, and J.R. Grierson Kinetic modeling of 3′-deoxy-3′-fluorothymidine in somatic tumors: Mathematical studies J Nucl Med 46 2005 371 380
17. T.Y. Seiwert, D.J. Haraf, and E.E. Cohen Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer J Clin Oncol 26 2008 1732 1741
18. J.K. Salama, D.J. Haraf, and K.M. Stenson A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers Ann Oncol 22 2011 2304 2309
19. M.G. Fury, N.Y. Lee, and E. Sherman A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer Cancer 118 2012 5008 5014
20. N.Y. Lee, Q. Zhang, and D.G. Pfister Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): A phase 2 multi-institutional trial Lancet Oncol 13 2012 172 180
21. D.S. Yoo, J.P. Kirkpatrick, and O. Craciunescu Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer Clin Cancer Res 18 2012 1404 1414
22. J.D. Hainsworth, D.R. Spigel, and F.A. Greco Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: A phase II trial of the Sarah Cannon oncology research consortium Cancer J 17 2011 267 272
23. C.H. Crane, L.M. Ellis, and J.L. Abbruzzese Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer J Clin Oncol 24 2006 1145 1151
24. C.G. Willett, D.G. Duda, and E. di Tomaso Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study J Clin Oncol 27 2009 3020 3026
25. A.M. Traynor, G.M. Richards, and G.K. Hartig Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: The University of Wisconsin experience Head Neck 32 2010 599 606
26. A. Sharma, B.K. Mohanti, and A. Thakar Concomitant chemoradiation versus radical radiotherapy in advanced squamous cell carcinoma of oropharynx and nasopharynx using weekly cisplatin: A phase II randomized trial Ann Oncol 21 2010 2272 2277
27. Z. Otty, M.B. Skinner, and J. Dass Efficacy and tolerability of weekly low-dose cisplatin concurrent with radiotherapy in head and neck cancer patients Asia Pac J Clin Oncol 7 2011 287 292
28. A. Homma, N. Inamura, and N. Oridate Concomitant weekly cisplatin and radiotherapy for head and neck cancer Jpn J Clin Oncol 41 2011 980 986
29. M. Mangoni, M.C. Vozenin, and G. Biti Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: Hurdles might be ahead Br J Cancer 107 2012 308 314
30. C.B. Hess, D.L. Rash, and M.E. Daly Competing causes of death and medical comorbidities among patients with human papillomavirus-positive vs human papillomavirus-negative oropharyngeal carcinoma and impact on adherence to radiotherapy JAMA Otolaryngol Head Neck Surg 140 2014 312 316
31. E. Schellhaas, C. Loddenkemper, and A. Schmittel Bowel perforation in non-small cell lung cancer after bevacizumab therapy Invest New Drugs 27 2009 184 187
32. E.M. Ryan, A. Hanly, and M.M. Morrin Unusual ischemic complication of bevacizumab treatment for metastatic colorectal carcinoma J Clin Oncol 31 2013 e433 e434
33. F. Elice, F. Rodeghiero, and A. Falanga Thrombosis associated with angiogenesis inhibitors Best Pract Res Clin Haematol 22 2009 115 128
34. T.J. Kruser, D.L. Wheeler, and E.A. Armstrong Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors Clin Cancer Res 16 2010 3639 3647
35. C. Timke, H. Zieher, and A. Roth Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy Clin Cancer Res 14 2008 2210 2219
36. S.M. Bentzen Repopulation in radiation oncology: Perspectives of clinical research Int J Radiat Biol 79 2003 581 585
37. P. Carmeliet, and R.K. Jain Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases Nat Rev Drug Discov 10 2011 417 427
38. S. Masunaga, Y. Liu, and H. Tanaka Reducing intratumour acute hypoxia through bevacizumab treatment, referring to the response of quiescent tumour cells and metastatic potential Br J Radiol 84 2011 1131 1138
39. K.J. Williams, B.A. Telfer, and A.M. Shannon Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: Pathophysiologic effects and therapeutic benefit Mol Cancer Ther 6 2007 599 606
40. M.J. Nyflot, P.M. Harari, and S. Yip Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx Radiother Oncol 105 2012 36 40